Home /Research /181P TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study

OTHER

181P TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study

Zhiyong Huang, J. Zhou, Meng Yang, Weidong Zhang, Yu Sun, Hongwei Lu, Hua Wang, Xinyu Bi, Ying Zhang, Jian Zhao, Yi Yang, Baoquan Zhang, F. Ye, Hong Zhao

Year: 2023
Citations: 2
Access: Open access

Keywords

MedicineHepatocellular carcinomaPerioperativeClinical endpointRegimenInternal medicinePhases of clinical researchGastroenterologySurgeryOncology

181P TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study

Keywords

Related papers

Statistical Learning Theory

Fractional Differential Equations

Applied Nonlinear Control

Genetic Programming: On the Programming of Computers by Means of Natural Selection